Clinical trials: Hospitalized COVID-19
Respiratory Distress Syndrome
The ECOVITA Study - Validation of LUS Score in SARS-CoV-2 Disease, i.e COVID-19
Lung Ultrasound (LUS) has been revealing an extremely useful tool to identify and monitor complications from Sars-COV-2 disease.
- Trial name
- ECOVITA (NCT04871685)
- Testing
- lung ultrasound
- Where
- Italy
- Volunteers
- 950 people
- Sponsor
- University of Campania Luigi Vanvitelli
COVID-19
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19.
- Trial name
- NCT04880109
- Testing
- APX-115
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Aptabio Therapeutics, Inc.
COVID-19
AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of AZD7442 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780437
- Testing
- AZD7442, Remdesivir
- Where
- 124 sites in United States, Denmark and 7 more
- Volunteers
- 1,455 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19
This study is open to adults with mild to moderate symptoms of COVID-19 (coronavirus disease). The purpose of this study is to find out whether a medicine called BI 767551 helps people with COVID-19.
- Trial name
- NCT04822701
- Testing
- BI 767551 intravenous, BI 767551 inhaled
- Where
- 5 sites in United States, Spain
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
COVID-19
Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19
The purpose of the study is to assess the safety and efficacy of ATR-002 (in addition to standard-of-care) for the treatment of COVID-19
- Trial name
- RESPIRE (NCT04776044)
- Testing
- ATR-002
- Where
- 40 sites in Germany, India and 5 more
- Volunteers
- 133 people
- Sponsor
- Atriva Therapeutics GmbH
COVID-19
Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
This is open-labe randomized multicenter comparative Phase III study conducted in 5 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in…
- Trial name
- NCT04542694
- Testing
- Favipiravir, Standard of care
- Where
- 5 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Promomed, LLC
Covid-19
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19
Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19
- Trial name
- SOC (NCT04440007)
- Testing
- Abivertinib, Standard of Care
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study…
- Trial name
- NCT05261139
- Testing
- nirmatrelvir, ritonavir
- Where
- 73 sites in United States, Bulgaria and 5 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
Corona Virus Infection, SARS-CoV 2
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
This is a single arm phase II trial to assess efficacy and confirm safety of infusions of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms,with or without confirmed interstitial…
- Conditions
- Corona Virus Infection, SARS-CoV 2, SARS Pneumonia, Pneumonia
- Trial name
- NCT04374565
- Testing
- High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Virginia
COVID, Hypertension
Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19
Hospitalized patients with COVID-19 will be included in the study in centers around Poland. After the hospitalization, a short questionnaire will be completed, including pre-hospitalization diagnoses, pre-hospitalization…
- Conditions
- COVID, Hypertension, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- COR-CARDIO (NCT04374110)
- Testing
- Clinical data
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Covid19
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of BGE-175 in participants ≥ 50 years of age hospitalized with documented COVID-19.
- Trial name
- NCT04705597
- Testing
- BGE-175
- Where
- 26 sites in United States, Argentina and 1 more
- Volunteers
- 194 people
- Sponsor
- BioAge Labs, Inc.
SARS-COV2, COVID19
Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV
Since December 2019, China and then the rest of the world have been affected by the rapid spread of a new coronavirus infection called SARS-CoV-2 (severe acute respiratory syndrome coronavirus), the clinical expression of which…
- Trial name
- REPERCOV (NCT04561154)
- Testing
- questionnaire
- Where
- France
- Volunteers
- 134 people
- Sponsor
- Centre Hospitalier le Mans
SARS-CoV-2
Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry
The infection caused by COVID19 worldwide makes it necessary to monitor drugs administered for the treatment of patients hospitalized with SARS-CoV-2.
- Trial name
- RegCOVID19 (NCT04347278)
- Testing
- Patients with the treatment agains COVID19
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
COVID-19 Pneumonia
Ozone Auto-hemotherapy for COVID-19 Pneumonia
This is a multicenter, randomized, controlled, open-label clinical trial testing the use of ozone auto-hemotherapy in hospitalized patients with Covid-19 pneumonia.
- Trial name
- COVID-OZONE (NCT04370223)
- Testing
- Ozone auto-hemotherapy
- Where
- 10 sites in Spain
- Volunteers
- 208 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Severe Acute Respiratory Syndrome Coronavirus 2
Pro-thrombotic Status in Patients with SARS-Cov-2 Infection
The present study is ideated to prospectively investigate in patients with severe acute respiratory syndrome (SARS) due to Coronavirus 19 (SARS-Cov-2) infection and moderate-severe respiratory failure the patterns and changes in…
- Trial name
- ATTAC-Co (NCT04343053)
- Testing
- SARS-Cov-2 infection
- Where
- Italy
- Volunteers
- 145 people
- Sponsor
- University Hospital of Ferrara
COVID-19
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of PF-07304814 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780541
- Testing
- PF-07304814, Remdesivir
- Where
- 40 sites in United States, Denmark
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV 2
Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study
A number of clinical features suggest the possibility of dysautonomia in patients infected with SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).
- Trial name
- COVIDANS (NCT04374045)
- Testing
- ECG-Holter
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)
In December 2019, a group of patients with pneumonia of unknown cause was identified in Wuhan, in the Hubei province, China. Despite the need of target specific therapeutic options for COVID-19, until now there is no proof of…
- Trial name
- COALITION-V (NCT04466540)
- Testing
- Hydroxychloroquine
- Where
- 69 sites in Brazil
- Volunteers
- 1,372 people
- Sponsor
- Hospital Alemão Oswaldo Cruz
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
- Trial name
- ILIAD-7-US-I (NCT04442178)
- Testing
- CYT107
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Revimmune